STOCK TITAN
  1. Home
  2. News
  3. LQDA

Liquidia Corp - LQDA STOCK NEWS

Welcome to our dedicated news page for Liquidia (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Liquidia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Liquidia's position in the market.

News
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced that Dr. Roger Jeffs, CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available via live webcast on Liquidia's website, with a replay and transcript archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences
-
News
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision by the Patent Trial and Appeal Board, leading the company to pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation. The company will also seek to set aside the injunction issued by the U.S. District Court and dismiss all claims related to the ‘793 patent in the second Hatch-Waxman lawsuit filed by United Therapeutics. Liquidia intends to defend itself against the allegations and focus on seeking final FDA approval for YUTREPIA to treat PAH and PH-ILD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
-
News
Liquidia Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16, resulting in total gross proceeds of approximately $25.0 million. The net proceeds are expected to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder, continue development of YUTREPIA in other clinical trials, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
offering
News
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) reported financial results for Q3 2023, with cash totaling $76.2 million. They are preparing for upcoming key events, including an appeal of a PTAB decision on December 4, 2023, and the PDUFA goal date on January 24, 2024, for adding a PH-ILD indication to YUTREPIA's label.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
earnings
-
News
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) will report its Q3 2023 financial results on November 7, 2023. A webcast will be held at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
conferences earnings
-
News
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
Rhea-AI Summary
Liquidia Corporation's amendment for YUTREPIA's new drug application has been accepted by the FDA for review. If approved, YUTREPIA would be indicated for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA has set a PDUFA goal date of January 24, 2024. The addition of the PH-ILD indication does not require new clinical studies. However, the launch of YUTREPIA is subject to ongoing litigation with United Therapeutics and final FDA approval. The FDA may not grant final approval for the PH-ILD indication until after the expiration of new clinical investigation exclusivity granted to Tyvaso on March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
clinical trial
News
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
Rhea-AI Summary
Liquidia Corporation faces patent infringement action by United Therapeutics Corporation under the Hatch-Waxman Act in response to Liquidia's amendment to its NDA for YUTREPIA. The '793 patent, previously ruled invalid by the PTAB, is asserted in the litigation, triggering a regulatory stay on FDA's final approval of YUTREPIA. The appeal of the PTAB decision is expected to be completed in Q4 2023 or H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
-
News
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Liquidia Corporation reports financial results for Q2 2023, including advancements in their mission to become the leading inhaled treprostinil provider for pulmonary hypertension patients. The company also provides updates on ongoing litigation, an amendment to add PH-ILD indication to their drug application for YUTREPIA, and a partnership to develop L606. Financially, the company's cash totaled $88.2 million as of June 30, 2023, and revenue increased to $4.8 million compared to the same period last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
earnings
-
News
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
conferences earnings
News
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
Rhea-AI Summary
Liquidia Corporation (LQDA) submits an amendment to the NDA for YUTREPIA to add PH-ILD indication without requiring new clinical data. Recertifies that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso. Potential launch of YUTREPIA between end of 2023 to mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
none
Stock LQDA logo
Liquidia Corp

Nasdaq:LQDA

LQDA Rankings

#2422 Ranked by Market Cap
#717 Ranked by Stock Gains
N/A Ranked by Dividends

LQDA Stock Data

1.06B
49.94M
12.42%
51.22%
9.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Durham

About LQDA

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.